Stemline Therapeutics (Stemline Therapeutics) Cash-to-Debt : 136.02 (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Stemline Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Stemline Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2020 was 136.02.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Stemline Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2020.

The historical rank and industry rank for Stemline Therapeutics's Cash-to-Debt or its related term are showing as below:

STML's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.49
* Ranked among companies with meaningful Cash-to-Debt only.

Stemline Therapeutics Cash-to-Debt Historical Data

The historical data trend for Stemline Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Stemline Therapeutics Cash-to-Debt Chart

Stemline Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

117.79

Stemline Therapeutics Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Cash-to-Debt	Get a 7-Day Free Trial															67.51	65.21	130.25	117.79	136.02

Competitive Comparison of Stemline Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Stemline Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stemline Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stemline Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Stemline Therapeutics's Cash-to-Debt falls into.

Stemline Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Stemline Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	164.431	/	(1.17	+	0.226)
	=	117.79

Stemline Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	151.524	/	(0.909	+	0.205)
	=	136.02

Stemline Therapeutics (NAS:STML) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Stemline Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Stemline Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Stemline Therapeutics (Stemline Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stemline Therapeutics Inc (NAS:STML) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022

Website

http://www.stemline.com

Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an immunotherapy). The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.

Executives

Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Kenneth J Zuerblis	director	20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Kenneth Hoberman	officer: Chief Operating Officer	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Ron Bentsur	director	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Alan S Forman	director	55 WHITNEY AVENUE, 5TH FLOOR, NEW HAVEN CT 06511
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Eric K Rowinsky	officer: Chief Medical Officer	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014